Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19

Abstract

Background and Objective Many patients treated for COVID-19 related acute respiratory distress syndrome in the intensive care unit are sedated with the benzodiazepine midazolam. Midazolam undergoes extensive metabolism by CYP3A enzymes, which may be inhibited by hyperinflammation. Therefore, an exaggerated proinflammatory response, as often observed in COVID-19, may decrease midazolam clearance. To develop a population pharmacokinetic model for midazolam in adult intensive care unit patients infected with COVID-19 and to assess the effect of inflammation, reflected by IL-6, on the pharmacokinetics of midazolam. Methods Midazolam blood samples were collected once a week between March 31 and April 30 2020. Patients were excluded if they concomitantly received CYP3A4 inhibitors, CYP3A4 inducers and/or continuous renal replacement therapy. Midazolam and metabolites were analyzed with an ultra-performance liquid chromatography–tandem mass spectrometry method. A population pharmacokinetic model was developed, using nonlinear mixed effects modelling. IL-6 and CRP, markers of inflammation, were analyzed as covariates. Results The data were described by a one-compartment model for midazolam and the metabolites 1-OH-midazolam and 1-OH-midazolam-glucuronide. The population mean estimate for midazolam clearance was 6.7 L/h (4.8–8.5 L/h). Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP. The midazolam clearance was reduced by 24% (6.7–5.1 L/h) when IL-6 increases from population median 116 to 300 pg/mL. Conclusions Inflammation, reflected by high IL-6, reduces midazolam clearance in critically ill patients with COVID-19. This knowledge may help avoid oversedation, but further research is warranted. Supplementary Information The online version contains supplementary material available at 10.1007/s40262-022-01122-5.

Population Pharmacokinetics of Dexamethasone in Critically Ill Covid-19 Patients: Does Inflammation Play a Role?

“…The negative correlation between inflammation levels and drug clearance, where higher CRP or IL-6 results in lower clearance, had been observed in previous studies in this population for other drugs (midazolam, voriconazole) as well [39,40]. However, for dexamethasone the situation is even more complex since the dexamethasone itself could reduce the inflammation, so it is more difficult to distinguish the cause/ result direction.…”

Analysis of factors related to prolonged midazolam action: A multicenter, case-control study

“…Critically ill patients with respiratory failure due to various conditions are often managed with deep sedation for prone positioning therapy and ventilator entrainment [23]. Therefore, the dose and duration of sedation may be prolonged, leading to the prolonged action of midazolam [24,25].…”

Usefulness of Inhaled Sedation in Patients With Severe ARDS Due to COVID-19

“…This practice has been related to a greater number of days of mechanical ventilation and episodes of delirium in ICU patients. 37,38 Several hypotheses associated with the neurotropism of the virus due to episodes of hyperexcitation and agitation have been proposed, 39 which explains the need for deep sedation in patients in the initial phases of ARDS in order to achieve protective ventilation goals. In our study we found a median dose difference between approaches of 5.7 mg/h, which compared with those who received inhaled sedation, who did not require benzodiazepines, suggests a possible decrease in these complications described; however, the reduction we found was not statistically significant in the inhaled sedation group, RR 0.8 (95% CI 0.61-1.15, P ¼ .25).…”